he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源邮箱
下一页:全面性癫痫的后遗症研究
- 2022-04-26隐源性癫痫比率翻倍
- 2022-04-25哪些抗菌药物可诱发抑郁症?
- 2022-04-202013年亚太地区抗癫痫联合会抗癫痫药使用指南
- 2022-02-28男同性恋为什么会患癫痫病 癫痫病症状
- 2022-01-24早期癫痫病症状发挥是什么
- 2021-12-13小儿癫痫病症状展现
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 癫痫猝死:凶手是谁?
- FDA批准Aptiom用于治疗患者癫痫发作
- GW制药Epidiolex治疗Dret综合征获得欧盟孤儿药资格
- 美国神经病学协会的新指南帮助医生HIV癫痫药物更适合患者
- 抗癫痫药物预防新发癫痫:任重而道远
- 上海率先探索异地就医门诊费直接结算
- 癫痫的病因是什么?
- 睡觉时突然抽搐 新生儿睡觉抽搐怎么办?
- 新版医保药品2800种 逢进必谈有哪些药?我们来看看!
- 月经性癫痫患者妊娠期癫痫控制更好
- 特发性癫痫大发作药物治疗的首选
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 预测癫痫患者再入院风险
- 综述:癫痫持续状态诊治最新进展
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 如何用科学的方法治疗癫痫?
- 羊角病能生孩子吗?
- UCB的Vimpat癫痫新适应症在美国获批
- 被WHO推荐,IVD国产替代品在结核病诊断领域取得了新的成果
- 青少年癫痫如何诊断?
- 儿童癫痫的早期症状 癫痫的原因
- 三庚酸酯可治疗1型转运体缺陷综合征
- FDA警告怀孕期间使用丙戊酸钠药物
- 癫痫需要如何诊断?
- 癫痫治疗障碍仍难以克服
- 药企实验室(研发/QC)规约管理与 ICH指南及药典最新进展
- FDA对怀孕期间使用丙戊碳酸类药物发出警告
- 不注意这些关键问题,吃多少药都没用!
- 治癫痫病众所周知的方法哪些呢
- NeuroImage:纤维进球成像可用于癫痫疾病进展
- 父母怎样分辨孩子其实癫痫?出现这些症状,家长不可大意!
- Sage罕见病明星药物荣膺FDA快速审批承诺
- CARS2:新的致痫基因组
- 第四届全国临床心电图实用基础理论和实践操作培训班
- 热性惊厥处理指南表述
- Neurology:颅脑损伤缩减迟发性癫痫发生风险,高损伤频率、重伤、老年人尤甚
- 治疗癫痫病选哪家公立医院比较好
- 世界癫痫日 | 科学防治 规约诊疗 告别癫痫
- 天使马什:小儿癫痫有哪些症状特征?